|Bid||155.01 x 200|
|Ask||180.00 x 100|
|Day's Range||164.58 - 166.27|
|52 Week Range||140.10 - 172.17|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.07%|
Small-cap stocks and the related exchange traded funds are often prized for their growth prospects and small-cap ETFs are explicitly dedicated to the growth factor, including the popular Vanguard Small-Cap ...
Although stocks have recently given back some of their short-term gains, the market big picture remains within the frame of momentum, which makes for a good environment to look to growth exchange-traded funds (ETFs).
The Zacks Analyst Blog Highlights: Select Sector SPDR Technology, Vanguard Small-Cap Growth, iShares MSCI ACWI, EventShares U.S. Tax Reform and Vanguard Value
After negotiating on two versions of the bill already passed by the House and Senate, Republicans unveiled their final tax bill — which would reshape the tax code in three decades, making America more competitive. The Congress will vote on the legislation on Tuesday and sent it to President Donald Trump for his signature by the end of the year.Source: Shutterstock
The Zacks Analyst Blog Highlights: Vanguard Small-Cap Growth, iShares S&P Small-Cap 600 Growth and Vanguard S&P Small-Cap 600 Growth
When you’re putting together a portfolio — whether you’re starting one tomorrow, or you’re looking to tinker with what you’ve got — there are a few basics that most investors aim for: U.S. stocks. International holdings. Fixed income.
Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.
Small-capitalization stock investors were defensive going into the 2017, but they have quickly changed their tune, turning to more growth-weighted smaller company picks. Investors can also gain diversified ...
Acadia Pharmaceuticals (ACAD) plans to focus on long-term care (or LTC) facilities to boost Nuplazid’s adoption in the Parkinson’s disease (or PD) psychosis indication.
In 1Q17, Bioverativ’s Eloctate witnessed revenues close to $155.9 million, which is about $48.0 million more YoY (year-over-year).
Abiomed (ABMD) reported a ~100% reorder rate in fiscal 4Q17, amounting to around $103.3 million, which was 34% higher on a YoY basis.
In 1Q17, Align Technology (ALGN) witnessed an 11.4% sequential rise in the volume of Invisalign cases used by doctors in international markets.
As the market tries to digest the surprising UK election results and Thursday’s testimony by ex FBI chief James Comey there is one market sector that is starting to emerge as a new leader. Many Wall Street pros are either not bullish on the small cap stocks or are negative but why?
Zacks Value Investor Highlights: Vanguard Small Cap Value ETF, Vanguard Small-Cap Growth ETF, CAI International, Energy Recovery and Rocky Brands
Exelixis is now developing a strong sales team to support the commercial launch of Cabometyx for indications like first-line RCC and second-line HCC.